MKI67 and neoplasm: 2f). In agreement with tumor growth rates, the percentage of Ki67-positive proliferating cells in AP20187-treated control tumors was significantly higher than that in vehicle-treated control tumors, while the percentages of Ki67-positive cells in both vehicle- and AP20187-treated FOXQ1-knockdown tumors were significantly lower than that in both vehicle- and AP20187-treated control tumors (Fig.